GVR Report cover Body Fluid Collection And Diagnostics Market Size, Share & Trends Report

Body Fluid Collection And Diagnostics Market Size, Share & Trends Analysis Report By Sample Type, By Products, By Technology, By Application (Prognostics & Screening, Diagnostics & Monitoring), By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453614
  • Number of Pages: 0
  • Format: Electronic (PDF)

Fluid samples for diagnostics offer many advantages such as early prognosis, cost effectiveness, and rapid results. They are used to analyze heterogeneous tumors and are also used for the analysis of tumor biomarkers. The ease of collection, storage, and analysis is fueling the demand for adoption of the body fluid collection and diagnostics.

Growing demand for disease diagnostics is positively impacting the growth of the market with novel techniques and products launched by the market players. For instance, in May 2022, TECHKON developed a device and method to analyze fluid samples for the determination of clinical parameters and instant diagnosis of blood, saliva, urine or any such sample on a card that initiates a biochemical reaction or a separation mechanism.

The leveraged demand for the analysis of body fluids in various clinical and diagnostic applications is likely to enhance the demand for instruments used for the collection and analysis of such samples during the forecast period. On the other hand, the increasing incidence of ailments along with numerous clinical trials fosters the growth of kits & reagents used for body fluid collection and diagnostics. For instance, in September 2021, Selux Diagnostics, Inc., declared that its next-generation phenotyping interface secured a designation of ‘breakthrough device’ by the U.S. FDA for analysis of sterile body fluid samples.

Body fluid samples are an abundance of natural biomarker proteins that essentially features the progression of a cancer condition. They are also used for the detection of such biomarkers for confirmation of a cancer condition. For instance, in January 2022, researchers of at the University of Illinois developed a technique to be used for the detection of cancer biomarkers in the body fluid samples. The detection and quantification of cancer-associated molecular biomarkers in such body fluids, are helpful for minimally invasive cancer detection.

The adaptive use of fluid-based tests over biopsy based diagnostic test offers advantages such as minimal invasion and relative ease of sample collection. The analysis of samples such as saliva and urine yield reliable outcomes in the diagnosis of biomarkers for genetic, metabolic, and infectious diseases. For instance, in June 2022, MultiOmic Health collaborated with Mesh Bio to carry out an observational clinical study on chronic metabolic diseases and their increased risk of complications by generating proteomic and metabolomics data from anonymized body fluid samples.

Moreover, the rise in demand for direct-to-consumer testing (DTC) is expected to increase the demand for body fluid collection, to facilitate easy sample collection by consumers. Many players dispatch the DTC sample collection kits directly to the consumers and thereby analyze the collected samples. For instance, in May 2021, Essenlix signed into a collaboration with Roche Diagnostics for deployment of its instant Mobile Self-Test (iMOST) platform to facilitate the patients with at-home testing procedures.

Rise in the incidence of diseases globally and the need for faster diagnosis is likely to positively impact the growth of the market. Body fluids are increasingly used for molecular diagnosis of disease conditions like cancers, genetic disorders, and infectious diseases. For instance, in May 2022, the Hitachi High-Tech Corporation collaborated with Invivoscribe, Inc., for acceleration of molecular diagnostics and precision medicine by integrating Invivoscribe's technology with Hitachi expertise in the analysis of system technologies.

                               Body Fluid Collection & Diagnostics Market Segmentation

Segments

Details

By Sample Type

  • Blood
  • Saliva
  • Urine
  • Cerebrospinal Fluid

By Products

  • Tests/Services
  • Kits & Consumables
  • Instruments

By Technology

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence in situ hybridization (FISH)
  • Others

By Application

  • Prognostics & screening
  • Diagnostics & monitoring
  • Therapeutic decision making

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Major companies operating in the market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Illumina, Inc., Guardant Health, QIAGEN N.V., Johnson & Johnson, Laboratory Corporation of America Holdings, Biocept Inc., F. Hoffmann-La Roche Ltd., MDxHealth SA.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon